Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
Adding daratumumab (Darzalex) to standard treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer (minimal residual disease) after treatment.
-
Under a new FDA approval, enzalutamide (Xtandi) can now be used alone, or in combination with leuprolide, to treat people with nonmetastatic prostate cancer that is at high risk of returning after surgery or radiation.
-
FDA approved toripalimab (Loqtorzi) based on the results of a large clinical trial showing that, when added to chemotherapy, the drug extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
-
In a clinical trial, a simple letter and phone call helped increase the number of people who completed the recommended follow-up testing after an abnormal cancer screening result.
-
In a clinical trial, people being treated for cancer who participated in virtual mind–body fitness classes were less likely to be hospitalized, and had shorter stays when they were hospitalized, than people who did not take the classes.
-
Tarlatamab, a new type of targeted immunotherapy, shrank small cell lung cancer (SCLC) tumors in more than 30% of participants in an early-stage clinical trial. Participants had SCLC that had progressed after previous treatments with other drugs.
-
For the first time in decades, people with advanced bladder cancer have more effective treatment options. New clinical trial results mark a pivotal moment following years of little progress, bladder cancer experts believe.
-
FDA has changed its 2021 approval of pembrolizumab (Keytruda) along with trastuzumab (Herceptin) and chemotherapy for treating HER2-positive stomach or GEJ cancer. The agency also announced a new approval of pembrolizumab for HER2-negative forms of these same cancers.
-
For people with lung cancer and medullary thyroid cancer whose tumors have changes in the RET gene, selpercatinib improved progression-free survival compared with other common treatments, according to new clinical trial results.
-
Stereotactic body radiotherapy was effective in people with localized kidney cancer who weren’t able to have surgery to remove their tumor, a clinical trial has shown. No patients had their cancer start growing or died from cancer over the next 5 years.